TOP TEN perturbations for 39857_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39857_at
Selected probe(set): 210190_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39857_at (210190_at) across 6674 perturbations tested by GENEVESTIGATOR:
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-4.187316Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):-3.7204504Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.5438843Number of Samples:58 / 74
Experimental | precursor-B-ALL study 1 (t(12;21)(p12,q22)) |
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
B-ALL study 1 (hyperdiploid) / normal bone marrow sample
Relative Expression (log2-ratio):-3.3634167Number of Samples:40 / 74
Experimental | B-ALL study 1 (hyperdiploid) |
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.332327Number of Samples:36 / 74
Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
heat shock study 1 (LPS) / untreated THP-1 cell sample
Relative Expression (log2-ratio):3.1744347Number of Samples:3 / 3
Experimental | heat shock study 1 (LPS) |
Cultured THP-1 mononuclear cells were treated with heat shock (43°C; 1h) and lipopolysaccharide (1ug/ml; 4h). | |
Control | untreated THP-1 cell sample |
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):3.1415462Number of Samples:2 / 2
Experimental | T-cell activation study 2 |
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
Control | quiescent CD4+ T-cell sample |
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample
Relative Expression (log2-ratio):-3.1088514Number of Samples:70 / 74
Experimental | precursor-B-ALL study 1 (t(11q23)) |
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
c-ALL/pre-B-ALL study 1 / normal bone marrow sample
Relative Expression (log2-ratio):-3.0707598Number of Samples:232 / 74
Experimental | c-ALL/pre-B-ALL study 1 |
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):-2.9381618Number of Samples:7 / 12
Experimental | IL-4; GM-CSF study 1 (intermediate) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |